MedTrace Logo

XPO-1 in Combination With RCHOP for DH/TH Lymphoma

NCT05974085 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-08-03

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy and safety of Selinexor in combination with RCHOP in first-line treatment of patients with DH or TH lymphoma.

Conditions

  • Double Hit Lymphoma
  • Triple Hit Lymphoma

Interventions

DRUG

Selinexor+RCHOP

XPO-1 inhibitor selinexor in combination with RCHOP

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Cong Li · Zhejiang Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-12-31
Completion
2024-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05974085 on ClinicalTrials.gov